Somatostatin analogs and intermediates thereto
AssigneeEli Lilly and Company
InventorJames E. Shields
Life of this patent
Estimating the term…
Abstract
The tetradecapeptides ##STR1## in which Y is Gly or D-Ala are described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptides. The tetradecapeptide in which Y is Gly as well as its pharmaceutically acceptable acid addition salts exhibit as their principal activity the in vivo inhibition of the release of gastric acid. The tetradecapeptide in which Y is D-Ala as well as its pharmaceutically acceptable acid addition salts exhibit as their principal activity the in vivo stimulation of the release of growth hormone.
Claims19
A compound selected from those of the formula ##STR10## and its pharmaceutically acceptable non-toxic acid addition salts, and R-L-Ala-Y-L-Cys(R.sub.1)-D-Lys(R.sub.2)-L-Asn-L-Phe-L-Phe-L-Trp(R.sub.5)-L -Lys(R.sub.2)-L-Thr(R.sub.3)-L-Phe-L-Thr(R.sub.3)-L-Ser(R.sub.4)-L-Cys(R.su b.1)-X;
- in which
- Y is Gly or D-Ala;
- R is hydrogen or an .alpha.-amino protecting group;
- R.sub.1 is hydrogen or a thio protecting group;
- R.sub.2 is hydrogen or an .epsilon.-amino protecting group;
- R.sub.3 and R.sub.4 each are hydrogen or a hydroxy protecting group;
- R.sub.5 is hydrogen or formyl;
- and
- X is hydroxy or ##STR11## in which the resin is polystyrene;
- with the proviso that, when X is hydroxy, each of R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 is hydrogen, and, when X is ##STR12## each of R, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 is other than hydrogen.
Dependencies are inferred from the claim text.